A new analysis suggests hypermutation can occur in some chemotherapy-treated gliomas, producing heterogeneous, mutation-rich tumors with poor response to anti-PD-1 treatment.
With TMB as a CDx, the drug will be available to more patients as a salvage option, but doctors will still need to consider the complex biomarker amid evolving research.
The study suggests that pediatric low-grade gliomas driven by genetic rearrangements tend to be diagnosed earlier and have better outcomes than those driven by SNVs.
The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.
Members of a large, international consortium tapped into whole-genome sequences from nearly 2,700 tumors to explore coding and non-coding variants contributing to cancer.
Using corrected TMB and other variables allowed Johns Hopkins researchers to more accurately predict response to immune checkpoint blockade in lung cancer.
In addition to developing standards for proteomics, metabolomics, and other kinds of data, DNAnexus will develop tools to help reviewers quickly and easily assess analysis pipelines.
The company has multiple companion diagnostics partnerships in the works, with new tests on the way in 2020, and new plans for next-generation sequencing.
Recent studies question the clinical utility of tumor mutational burden as a biomarker for immuno-oncology response, and the FDA clearance includes no therapeutic indications.
